Simon A Jones Selected Research

olipudase alfa

1/2021	One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.
1/2021	Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.
1/2016	Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
9/2015	Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon A Jones Research Topics

Disease

34	Inflammation (Inflammations) 10/2022 - 08/2003
20	Mucopolysaccharidoses 04/2022 - 01/2011
14	Mucopolysaccharidosis I (Hurler Syndrome) 11/2021 - 08/2011
14	Arthritis (Polyarthritis) 01/2021 - 09/2003
9	Infections 10/2022 - 11/2002
9	Rheumatoid Arthritis 01/2020 - 05/2005
7	Mucopolysaccharidosis II (Hunter Syndrome) 04/2022 - 10/2010
7	Mucopolysaccharidosis III (Sanfilippo Syndrome) 12/2021 - 01/2011
7	Neoplasms (Cancer) 12/2018 - 04/2005
6	Peritonitis 01/2018 - 11/2002
5	Wolman Disease (Wolman's Disease) 03/2021 - 11/2014
5	Niemann-Pick Diseases (Niemann Pick Disease) 01/2021 - 09/2015
5	Disease Progression 01/2018 - 08/2008
4	COVID-19 01/2022 - 01/2020
4	Experimental Arthritis 01/2021 - 09/2003
4	Chronic Disease (Chronic Diseases) 12/2018 - 09/2005
3	Lysosomal Storage Diseases (Lysosomal Storage Disease) 04/2022 - 02/2015
3	Gaucher Disease (Gaucher's Disease) 01/2022 - 12/2020
3	Neurologic Manifestations (Neurological Manifestations) 01/2022 - 01/2016
3	Glycogen Storage Disease Type II (Pompe's Disease) 06/2019 - 01/2012
3	Hypersensitivity (Allergy) 01/2018 - 11/2014
3	Fibrosis (Cirrhosis) 11/2016 - 01/2014
3	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2015 - 01/2011
3	Neuroinflammatory Diseases 10/2013 - 01/2012
3	Human Influenza (Influenza) 10/2013 - 02/2008
2	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 03/2022 - 01/2018
2	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 08/2014
2	Critical Illness (Critically Ill) 12/2020 - 05/2020
2	Mucopolysaccharidosis VII (Sly Syndrome) 05/2019 - 01/2019
2	Mucopolysaccharidosis IV (Morquio Syndrome) 01/2019 - 03/2018
2	Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy) 01/2019 - 08/2014
2	Dysostoses 01/2019 - 03/2016
2	Sleep Wake Disorders 01/2019 - 01/2019
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2016 - 10/2016
2	Hip Dislocation 03/2016 - 10/2013
2	Tertiary Lymphoid Structures 02/2016 - 10/2015
2	Lung Diseases (Lung Disease) 09/2015 - 07/2010
2	Bacterial Infections (Bacterial Infection) 12/2011 - 09/2005
2	Joint Diseases (Joint Disease) 11/2010 - 01/2002
2	Colonic Neoplasms (Colon Cancer) 08/2006 - 05/2005

Drug/Important Bio-Agent (IBA)

32	Interleukin-6 (Interleukin 6)IBA 01/2021 - 08/2003
20	CytokinesIBA 01/2021 - 08/2003
15	EnzymesIBA 01/2021 - 01/2011
10	Proteins (Proteins, Gene)FDA Link 10/2022 - 08/2003
10	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 11/2014 - 09/2003
9	GlycosaminoglycansIBA 04/2022 - 08/2011
8	AntigensIBA 12/2018 - 05/2006
7	LipidsIBA 01/2021 - 08/2009
7	ChemokinesIBA 11/2016 - 05/2004
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2015
4	Sebelipase alfaIBA 03/2021 - 11/2014
4	olipudase alfaIBA 01/2021 - 09/2015
4	AntibodiesIBA 06/2019 - 05/2006
4	human GALNS proteinIBA 01/2018 - 11/2014
4	idursulfase FDA Link 11/2017 - 10/2010
4	InterleukinsIBA 08/2014 - 01/2011
4	Cytokine Receptor gp130IBA 01/2011 - 09/2003
3	Biological ProductsIBA 10/2022 - 03/2013
3	AcidsIBA 01/2021 - 01/2012
3	Interleukin-27 (Interleukin 27)IBA 01/2020 - 10/2015
3	Pharmaceutical PreparationsIBA 06/2019 - 01/2016
3	Interleukin-10 (Interleukin 10)IBA 01/2016 - 08/2014
3	Matrix Metalloproteinases (MMPs)IBA 01/2014 - 01/2002
3	N-sulfoglucosamine sulfohydrolase (sulfamidase)IBA 10/2013 - 01/2011
2	Glucosylceramidase (Glucocerebrosidase)IBA 01/2022 - 12/2020
2	Lysergic Acid Diethylamide (LSD)IBA 01/2022 - 01/2019
2	heparan sulfate sulfataseIBA 12/2021 - 01/2016
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2021 - 09/2015
2	neodymium pyrocatechin disulfonate (NPD)IBA 01/2021 - 09/2015
2	C-Reactive ProteinIBA 05/2020 - 09/2014
2	Interleukin-17 (Interleukin 17)IBA 01/2020 - 10/2011
2	InterferonsIBA 01/2020 - 01/2014
2	Iduronidase (alpha-L-Iduronidase)IBA 10/2019 - 10/2015
2	vestronidase alfaIBA 05/2019 - 01/2019
2	N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B)IBA 01/2019 - 08/2014
2	human GAA protein (Myozyme)FDA Link 07/2017 - 01/2012
2	Antiviral Agents (Antivirals)IBA 04/2017 - 04/2014
2	Mitochondrial DNA (mtDNA)IBA 12/2016 - 10/2016
2	SphingomyelinsIBA 01/2016 - 09/2015
2	G(M2) Ganglioside (Ganglioside GM2)IBA 10/2013 - 01/2012
2	Heparitin Sulfate (Heparan Sulfate)IBA 10/2013 - 08/2012
2	Nicotinamide PhosphoribosyltransferaseIBA 07/2011 - 07/2006
2	EicosanoidsIBA 02/2011 - 08/2009
2	Interleukin-8 (Interleukin 8)IBA 07/2010 - 08/2005
2	Interleukin-1beta (Interleukin 1 beta)IBA 01/2010 - 07/2007
2	Interferon-gamma (Interferon, gamma)IBA 01/2010 - 07/2007
2	Oncostatin MIBA 08/2008 - 11/2002
2	Protein Isoforms (Isoforms)IBA 05/2006 - 05/2004
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2022
1	TransferasesIBA 10/2022

Therapy/Procedure

29	Enzyme Replacement Therapy 12/2021 - 10/2010
20	Therapeutics 01/2022 - 01/2002
10	Hematopoietic Stem Cell Transplantation 01/2022 - 08/2011
4	Stem Cell Transplantation 01/2022 - 03/2016
3	Artificial Respiration (Mechanical Ventilation) 12/2020 - 01/2011
3	Peritoneal Dialysis 01/2018 - 12/2011
2	Biological Therapy 01/2022 - 03/2013
2	Transplantation 01/2022 - 02/2016
2	Mechanical Ventilators (Ventilator) 10/2016 - 01/2011
2	Cell Transplantation 06/2015 - 03/2015